The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are “ultra-long-acting” and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an “ultra-rapid-acting” insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.
Diabetes mellitus is a multifaceted disease that yields various approaches in terms of diagnosis, treatment and drug delivery. Products for maintenance and treatment of diabetes can be of high volume and low cost or of relatively low volume and high cost. The U.S. diabetes monitoring, treatment and drug delivery market increased in value in 2016 and growth is expected to persist over the forecast period. Growth will be driven by the increasing prevalence of diabetes in the U.S. and technological advancements made in certain segments, particularly insulin pumps and continuous glucose monitoring (CGM). Limitations to market growth include pricing pressure due to recent CMS reimbursement changes and the negative impact on the overall blood glucose monitoring market. The recent influx of low-price competitors in the blood glucose test strip segment has also placed downward pressure on prices and resulted in market value contractions despite the growing volume and increasing number of diabetics testing their blood glucose levels.
'
TABLE OF CONTENTS I
LIST OF FIGURES III
LIST OF CHARTS V
EXECUTIVE SUMMARY 1
U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 7
MARKET DEVELOPMENTS 9
PROCEDURE NUMBERS 10
PROCEDURE CODES INVESTIGATED 10
MARKETS INCLUDED 11
KEY REPORT UPDATES 13
VERSION HISTORY 13
RESEARCH METHODOLOGY 14
1.1 RESEARCH SCOPE 14
1.2 IDATA’S 9-STEP METHODOLOGY 14
Step 1: Project Initiation & Team Selection 14
Step 2: Prepare Data Systems and Perform Secondary Research 16
Step 3: Preparation for Interviews & Questionnaire Design 17
Step 4: Performing Primary Research 18
Step 5: Research Analysis: Establishing Baseline Estimates 20
Step 6: Market Forecast and Analysis 21
Step 7: Identify Strategic Opportunities 23
Step 8: Final Review and Market Release 24
Step 9: Customer Feedback and Market Monitoring 25
DISEASE OVERVIEW 26
2.1 INTRODUCTION 26
2.1.1 Types of Diabetes 26
2.1.2 Diabetes Complications 28
2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes 30
2.1.4 Signs and Symptoms 31
2.1.5 Diabetes Monitoring 33
2.1.6 Treatment 35
2.1.7 Drug Delivery Systems 36
U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET OVERVIEW 38
3.1 MARKET OVERVIEW 38
3.2 TREND ANALYSIS 43
3.3 DRIVERS AND LIMITERS 47
3.3.1 Market Drivers 47
3.3.2 Market Limiters 48
3.4 COMPETITIVE MARKET SHARE ANALYSIS 51
3.5 MERGERS AND ACQUISITIONS 57
ABBREVIATIONS 58
Chart 1 1: Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S., 2013 – 2023 3
Chart 1 2: Diabetes Monitoring, Treatment and Drug Delivery Market Overview, U.S., 2013 &2023 3
Chart 3 1: Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S., 2013 – 2023 41
Chart 3 2: Diabetes Monitoring, Treatment and Drug Delivery Market Breakdown, U.S., 2016 42
Chart 3 3: Diabetes Monitoring, Treatment and Drug Delivery Market Breakdown, U.S.,2023 42
Chart 3 4: Growth Rates by Segment, Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2013 – 2023 46
Chart 3 5: Leading Competitors, Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2016 56
Figure 1 1: Diabetes Monitoring, Treatment and Drug Delivery Market Share Ranking by Segment, U.S., 2016 (1 of 2) 4
Figure 1 2: Diabetes Monitoring, Treatment and Drug Delivery Market Share Ranking by Segment, U.S., 2016 (2 of 2) 5
Figure 1 3: Companies Researched in this Report, U.S., 2016 6
Figure 1 4: Factors Impacting the Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S. (1 of 2) 7
Figure 1 5: Factors Impacting the Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S. (2 of 2) 8
Figure 1 6: Recent Events in the Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2013 – 2016 9
Figure 1 7: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 10
Figure 1 8: Procedure Codes Investigated, U.S., 2016 10
Figure 1 9: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 (1 of 2) 11
Figure 1 10: Diabetes Monitoring, Treatment and Drug Delivery Markets Covered, U.S., 2016 (2 of 2) 12
Figure 1 11: Key Report Updates 13
Figure 1 12: Version History 13
Figure 2 1: Major Types of Diabetes and Related Pathologies, U.S., 2016 27
Figure 2 2: Risk Factors Associated with Type 1 and Type 2 Diabetes, U.S., 2016 31
Figure 2 3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes, U.S., 2016 32
Figure 3 1: Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S., 2013 – 2023 (US$M) (1 of 2) 39
Figure 3 2: Diabetes Monitoring, Treatment and Drug Delivery Market by Segment, U.S., 2013 – 2023 (US$M) (2 of 2) 40
Figure 3 3: Growth Rates by Segment, Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2013 – 2023 (1 of 2) 44
Figure 3 4: Growth Rates by Segment, Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2013 – 2023 (2 of 2) 45
Figure 3 5: Drivers and Limiters, Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2016 50
Figure 3 6: Leading Competitors, Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2016 (1 of 2) 54
Figure 3 7: Leading Competitors, Diabetes Monitoring, Treatment and Drug Delivery Market, U.S., 2016 (2 of 2) 55
Sanofi
Novo Nordisk
Eli Lilly
Medtronic
Johnson & Johnson
Becton Dickinson
Abbott
Roche
DexCom
Ascensia
Insulet
Trividia Health
Tandem
Nova Biomedical
Valeritas
